Actively Recruiting
Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease: Insights From a Real-World Cohort
Led by IRCCS Ospedale San Raffaele · Updated on 2025-06-10
800
Participants Needed
2
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the relationship between plasma NT-proBNP levels and the presence, extent, and severity of artery narrowing in patients suspected of having coronary artery disease (CAD). This observational study focuses on patients referred for elective diagnostic coronary angiography based on symptoms or signs of CAD. The purpose is to better understand how NT-proBNP levels correlate with the burden of coronary artery disease in a real-world patient population. The study involves measuring plasma NT-proBNP levels in patients during hospitalization, specifically on the morning before their coronary angiography procedure. The extent and severity of coronary artery narrowing are independently assessed by two experienced cardiologists during and immediately after the angiography. Patients with conditions that may affect NT-proBNP levels, such as heart failure, severe valvular disease, atrial fibrillation, severe chronic kidney disease, prior coronary artery bypass surgery, or those over 80 years old are excluded to ensure accurate evaluation. Participants will undergo blood tests and coronary angiography as part of their regular hospital care. Researchers will analyze the NT-proBNP levels alongside angiographic findings to determine any associations. The primary outcome is the correlation between plasma NT-proBNP levels and the presence and severity of coronary artery lesions. The study began in September 2021 and is expected to conclude by July 2025, with no additional long-term follow-up reported.
CONDITIONS
Brief Title
Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient referred for elective coronary angiography due to suspected coronary artery disease.
- NT-proBNP measurement during hospitalization.
- Age 18 years or older.
You will not qualify if you...
- Heart failure.
- Severe valvular disease.
- Atrial fibrillation.
- Severe chronic kidney disease with eGFR less than 30 mL/min.
- Prior coronary artery bypass grafting.
- Age over 80 years.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo measurement of plasma NT-proBNP levels and elective coronary angiography to assess the presence and severity of coronary artery disease.
1 visit (in-person)
Duration - Up to 2 years
Participants are observed after the diagnostic procedures to evaluate the association between NT-proBNP levels and coronary artery disease burden.
Follow-up visits as per routine care
Trial Site Locations
Total: 2 locations
1
IRCCS San Raffaele Hospital
Milan, Italy, Italy, 20132
Completed
2
IRCCS San Raffaele Hospital
Milan, Italy, Italy, 20132
Actively Recruiting
Research Team
C
Carlo Gaspardone
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here